Latest Articles

Publication Date
Countdown is on for world first nasal spray to fight dementia - Herald Sun

Countdown is on for world first nasal spray to fight dementia Herald Sun

Published: Dec. 3, 2025, 6:05 p.m.
Study challenges menstrual taboo to promote more inclusive workplaces - FemTech World

Study challenges menstrual taboo to promote more inclusive workplaces FemTech World

Published: Dec. 3, 2025, 2:10 p.m.
Ariana Grande Shares Urgent Reminder About Body-Shaming As Her Past Claim Sparks Outrage - AOL.com

Ariana Grande Shares Urgent Reminder About Body-Shaming As Her Past Claim Sparks Outrage AOL.com

Published: Dec. 3, 2025, 11:25 a.m.
USC study reveals hidden cellular layers in the brain’s memory center - Keck School of Medicine of USC

USC study reveals hidden cellular layers in the brain’s memory center Keck School of Medicine of USC

Published: Dec. 3, 2025, 10:33 a.m.
Experts establish diagnostic criteria for primary dysmenorrhea - Contemporary OB/GYN

Experts establish diagnostic criteria for primary dysmenorrhea Contemporary OB/GYN

Published: Dec. 2, 2025, 4:47 p.m.
How invisible symptoms and provider bias delay endometriosis diagnosis - Contemporary OB/GYN

How invisible symptoms and provider bias delay endometriosis diagnosis Contemporary OB/GYN

Published: Dec. 2, 2025, 2:02 p.m.
Metri Bio Raises $5M Pre-Seed to Develop Endometriosis Therapeutics - Femtech Insider

Metri Bio Raises $5M Pre-Seed to Develop Endometriosis Therapeutics Femtech Insider

Published: Dec. 2, 2025, 1:03 p.m.
Ziwig Publishes Validation Study for Saliva-Based Endometriosis Test - Femtech Insider

Ziwig Publishes Validation Study for Saliva-Based Endometriosis Test Femtech Insider

Published: Dec. 2, 2025, 11:38 a.m.
Round up: First wearable detects symptoms of perimenopause, and more - FemTech World

Round up: First wearable detects symptoms of perimenopause, and more FemTech World

Published: Dec. 2, 2025, 11:04 a.m.
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia - Bayer

Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia Bayer

Published: Dec. 2, 2025, 7:30 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!